Vaccine Weekly

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly


We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Cancer Vaccine

Non-CpG motif oligonucleotides for cancer vaccination developed

According to recent research from Canada, "We have previously described a novel family of immunomodulatory synthetic oligonucleotides characterized by a phosphodiester backbone, a length of six bases and a 5'G₃ xG₂ 3' sequence, where x is A, C, G or T. In the present study, we have evaluated whether these 5G₃ xG₂ 3' oligonucleotides possess additional activities essential for adequate cancer vaccination. Immunization for the treatment of cancer requires an adjuvant, a source of tumor-associated antigen (s), for...

• View Other Issues of Vaccine Weekly
  
• View Other NewsRx Publications